Post‐COVID‐19‐associated multiorgan complications or “long COVID” with literature review and management strategy discussion: A meta‐analysis

Author:

Iqbal Phool1,Ata Fateen2ORCID,Chaudhry Hassan3,Muthanna Bassam4,Waqas Younas Hafiz5,Munamm Syed Ata ul6,Sharma Rohit7,Fadah Kahtan8,Elazzazy Shereen9,Hamad Anas10,Said Abu Tabar Osama11,Omar Nabil E.9ORCID

Affiliation:

1. Department of Internal Medicine New York Medical College/Metropolitan Hospital Center New York New York USA

2. Department of Endocrinology Hamad Medical Corporation Doha Qatar

3. Department of Respiratory Medicine University Hospital of Leicester Leicester UK

4. Department of Geriatrics University of Illinois at Chicago Chicago Illinois USA

5. NHS Lanarkshire Leicester UK

6. Department of Public Health Health Services Academy Islamabad Islamabad Pakistan

7. Department of Internal Medicine Geisinger Health System Danville Pennsylvania USA

8. Department of Internal Medicine Texas Tech University Health Sciences Center El Paso Lubbock Texas USA

9. Pharmacy Department National Centre for Cancer Care and Research, Hamad Medical Corporation Doha Qatar

10. Department of Clinical Pharmacology National Centre for Cancer Care and Research, Hamad Medical Corporation Doha Qatar

11. Cleveland Clinic Abu Dhabi, Clinical Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine Case Western Reserve University Abu Dhabi UAE

Abstract

AbstractObjectiveTo investigate the post‐COVID‐19 long‐term complications or long COVID of various organ systems in patients after 3 months of the infection, specifically before the Omicron variant, with comparative literature analysis.MethodsA systemic literature search and meta‐analysis were conducted using multiple electronic databases (PubMed, Scopus, Cochrane library) with predefined search terms to identify eligible articles. Eligible studies reported long‐term complications of COVID‐19 infection before the Omicron variant infection. Case reports, case series, observational studies with cross‐sectional or prospective research design, case–control studies, and experimental studies that reported post‐COVID‐19 complications were included. The complications reported after 3 months after the recovery from COVID‐19 infection were included in the study.ResultsThe total number of studies available for analysis was 34. The effect size (ES) for neurological complications was 29% with 95% confidence interval (CI): 19%–39%. ES for psychiatric complications was 24% with 95% CI: 7%–41%. ES was 9% for cardiac outcomes, with a 95% CI of 1%–18%. ES was 22%, 95% CI: 5%–39% for the gastrointestinal outcome. ES for musculoskeletal symptoms was 18% with 95% CI: 9%–28%. ES for pulmonary complications was 28% with 95% CI: 18%–37%. ES for dermatological complications was 25%, with a 95% CI of 23%–26%. ES for endocrine outcomes was 8%, with a 95% CI of 8%–9%. ES size for renal outcomes was 3% with a 95% CI of 1%–7%. At the same time, other miscellaneous uncategorized outcomes had ES of 39% with 95% CI of 21%–57%. Apart from analyzing COVID‐19 systemic complications outcomes, the ES for hospitalization and intensive care unit admissions were found to be 4%, 95% CI: 0%–7%, and 11% with 95% CI: 8%–14%.ConclusionBy acquiring the data and statistically analyzing the post‐COVID‐19 complications during the prevalence of most virulent strains, this study has generated a different way of understanding COVID‐19 and its complications for better community health.

Publisher

Wiley

Subject

General Medicine

Reference42 articles.

1. Long COVID: long‐term effects of COVID‐19.Johns Hopkins Medicine. Accessed August 1 2022. . Accessed August 1 2022. (june 2022)https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/covid-long-haulers-long-term-effects-of-covid19

2. The overall impact of COVID ‐19 on healthcare during the pandemic: A multidisciplinary point of view

3. Clues to long COVID

4. Long COVID or post‐COVID conditions.CDC. Accessed August 9 2022.https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html

5. Omicron Delta Alpha and More: what to know about the coronavirus variants.Yale Medicine. Accessed July 27 2022. Accessed July 27 2022.https://www.yalemedicine.org/news/covid-19-variants-of-concern-omicron

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3